Who are BG00002 (natalizumab)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): natalizumab (NTZ), Natalizumab (Tysabri).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bg00002-natalizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

BG00002 (natalizumab) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BG00002 (natalizumab) (BG00002 (natalizumab)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody (integrin antagonist). Area: Immunology / Neurology.

marketed Monoclonal antibody (integrin antagonist) α4β1 integrin Immunology / Neurology Biologic Live · refreshed every 30 min

Target snapshot

BG00002 (natalizumab) (BG00002 (natalizumab)) — Biogen. Natalizumab is a monoclonal antibody that blocks the α4β1 integrin on immune cells, preventing their migration across the blood-brain barrier into the central nervous system.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BG00002 (natalizumab) TARGET	BG00002 (natalizumab)	Biogen	marketed	Monoclonal antibody (integrin antagonist)	α4β1 integrin
natalizumab (NTZ)	natalizumab (NTZ)	University Hospital, Clermont-Ferrand	marketed	Monoclonal antibody (integrin antagonist)	α4β1 integrin (VLA-4)
Natalizumab (Tysabri)	Natalizumab (Tysabri)	Cornerstone Health Care, PA	marketed	Monoclonal antibody; integrin antagonist	α4β1 integrin (VLA-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody (integrin antagonist) class)

Biogen · 1 drug in this class
University Hospital, Clermont-Ferrand · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BG00002 (natalizumab) — Competitive Intelligence Brief. https://druglandscape.com/ci/bg00002-natalizumab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab